Stock listing
Munich:29A Amphastar Pharmaceuticals, Inc. Aktie
German listing (Munich) of Amphastar Pharmaceuticals, Inc. · home listing NASDAQ:AMPH
Follow Amphastar Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AMPH
$28.25 USD -1.46 (-4.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AMPH
- Day range
- $27.79 – $28.70 USDNov 20, 2026
- Volume
- 498,484 sharesNov 20, 2026
- Market cap
- $1.20B USDAt the close on Nov 20, 2026 · price × 42.65M shares outstanding
- 52-week range
- $16.65 – $31.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.06M USDMedian day 456,779 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AMPH · Home | $28.25 USD | -1.46 (-4.9%) | 498,484 | $28.14 | $28.70 | $27.79 | $29.71 | Close on Nov 20, 2026 |
| Frankfurt:29A | €25.45 EUR | -1.68 (-6.2%) | — | €25.03 | €25.45 | €25.03 | €27.13 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AMPH · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $28.25 | -1.46 | -4.9% | $28.14 | $28.70 | $27.79 | 498,484 | |
| $29.71 | +0.61 | +2.1% | $29.03 | $30.58 | $28.90 | 526,383 | |
| $29.10 | -0.07 | -0.2% | $28.87 | $29.38 | $28.21 | 409,724 | |
| $29.17 | -0.20 | -0.7% | $29.75 | $30.10 | $29.11 | 541,664 | |
| $29.37 | +0.50 | +1.7% | $29.05 | $29.73 | $28.84 | 380,762 | |
| $28.87 | +0.27 | +0.9% | $28.77 | $29.02 | $28.53 | 374,909 | |
| $28.60 | -0.46 | -1.6% | $28.87 | $29.30 | $28.50 | 497,663 | |
| $29.06 | -0.32 | -1.1% | $28.75 | $29.40 | $28.51 | 484,839 | |
| $29.38 | +0.89 | +3.1% | $28.74 | $29.70 | $28.50 | 635,802 | |
| $28.49 | +0.83 | +3.0% | $29.44 | $31.00 | $27.80 | 826,252 | |
| $27.66 | -0.36 | -1.3% | $28.31 | $29.21 | $27.43 | 607,331 | |
| $28.02 | +0.90 | +3.3% | $27.37 | $28.57 | $27.09 | 644,911 | |
| $27.12 | +0.09 | +0.3% | $27.04 | $27.39 | $26.85 | 550,212 | |
| $27.03 | -0.69 | -2.5% | $27.72 | $27.80 | $26.69 | 497,700 | |
| $27.72 | +0.79 | +2.9% | $27.12 | $27.80 | $26.76 | 664,503 | |
| $26.93 | +0.60 | +2.3% | $26.84 | $27.00 | $26.45 | 371,412 | |
| $26.33 | +0.76 | +3.0% | $25.36 | $26.36 | $25.36 | 397,263 | |
| $25.57 | +0.10 | +0.4% | $25.38 | $25.70 | $25.29 | 323,925 | |
| $25.47 | +0.33 | +1.3% | $25.27 | $25.65 | $25.22 | 225,242 | |
| $25.14 | -0.90 | -3.5% | $25.91 | $25.91 | $24.62 | 483,119 | |
| $26.04 | -0.16 | -0.6% | $26.25 | $26.50 | $25.92 | 315,088 | |
| $26.20 | +0.26 | +1.0% | $25.69 | $26.35 | $25.51 | 390,201 | |
| $25.94 | -0.20 | -0.8% | $26.24 | $26.61 | $25.82 | 361,336 | |
| $26.14 | +0.27 | +1.0% | $25.63 | $26.31 | $25.63 | 299,510 | |
| $25.87 | -0.55 | -2.1% | $26.61 | $26.61 | $25.52 | 352,084 | |
| $26.42 | +0.34 | +1.3% | $26.38 | $27.10 | $26.13 | 352,436 | |
| $26.08 | +0.03 | +0.1% | $25.89 | $26.57 | $25.89 | 364,655 | |
| $26.05 | -0.71 | -2.7% | $26.91 | $27.00 | $26.03 | 326,547 | |
| $26.76 | +0.14 | +0.5% | $26.62 | $26.86 | $26.51 | 362,818 | |
| $26.62 | +0.81 | +3.1% | $25.73 | $26.79 | $25.65 | 437,696 | |
| $25.81 | +0.27 | +1.1% | $25.39 | $26.14 | $25.10 | 423,536 | |
| $25.54 | -0.37 | -1.4% | $25.91 | $26.17 | $25.29 | 776,285 | |
| $25.91 | +0.54 | +2.1% | $25.54 | $26.13 | $25.03 | 469,146 | |
| $25.37 | -0.06 | -0.2% | $25.43 | $25.70 | $25.17 | 454,522 | |
| $25.43 | +0.08 | +0.3% | $25.46 | $25.55 | $25.06 | 374,220 | |
| $25.35 | -0.46 | -1.8% | $25.60 | $26.02 | $25.30 | 530,991 | |
| $25.81 | -0.87 | -3.3% | $26.73 | $26.79 | $25.77 | 509,363 | |
| $26.68 | -0.71 | -2.6% | $27.59 | $27.64 | $26.52 | 631,997 | |
| $27.39 | +1.26 | +4.8% | $25.99 | $27.80 | $25.96 | 751,801 | |
| $26.13 | -0.14 | -0.5% | $26.25 | $26.63 | $25.66 | 376,921 | |
| $26.27 | +1.31 | +5.2% | $24.81 | $26.31 | $24.65 | 572,080 | |
| $24.96 | +0.64 | +2.6% | $24.39 | $25.12 | $24.20 | 508,095 | |
| $24.32 | -0.16 | -0.7% | $24.60 | $24.83 | $24.00 | 522,394 | |
| $24.48 | +0.86 | +3.6% | $23.54 | $25.41 | $23.45 | 595,754 | |
| $23.62 | -0.20 | -0.8% | $23.69 | $23.99 | $23.51 | 1,455,803 | |
| $23.82 | -0.13 | -0.5% | $24.08 | $24.18 | $23.50 | 465,642 | |
| $23.95 | +0.31 | +1.3% | $23.64 | $24.39 | $23.49 | 503,880 | |
| $23.64 | -0.27 | -1.1% | $23.75 | $23.94 | $23.56 | 354,415 | |
| $23.91 | +0.13 | +0.5% | $23.84 | $24.28 | $23.56 | 474,878 | |
| $23.78 | +0.24 | +1.0% | $23.65 | $23.80 | $23.24 | 410,954 | |
| $23.54 | +0.50 | +2.2% | $23.00 | $23.69 | $22.76 | 514,990 | |
| $23.04 | +0.11 | +0.5% | $22.84 | $23.07 | $22.57 | 351,601 | |
| $22.93 | -0.25 | -1.1% | $22.82 | $23.14 | $22.30 | 460,015 | |
| $23.18 | -0.66 | -2.8% | $23.47 | $23.74 | $23.07 | 650,129 | |
| $23.84 | +0.10 | +0.4% | $23.88 | $23.92 | $23.04 | 469,751 | |
| $23.74 | +0.78 | +3.4% | $23.05 | $23.83 | $23.03 | 456,779 | |
| $22.96 | +0.43 | +1.9% | $22.59 | $23.05 | $22.59 | 550,979 | |
| $22.53 | +0.52 | +2.4% | $21.86 | $22.65 | $21.52 | 274,025 | |
| $22.01 | +0.13 | +0.6% | $21.88 | $22.15 | $21.69 | 224,533 | |
| $21.88 | -0.14 | -0.6% | $21.69 | $21.97 | $21.63 | 259,787 | |
| $22.02 | +0.04 | +0.2% | $21.86 | $22.44 | $21.72 | 395,610 | |
| $21.98 | +0.46 | +2.1% | $21.50 | $22.07 | $21.41 | 283,774 | |
| $21.52 | -0.08 | -0.4% | $21.60 | $21.81 | $21.26 | 210,263 | |
| $21.60 | -0.08 | -0.4% | $21.64 | $22.20 | $21.44 | 376,558 | |
| $21.68 | -0.06 | -0.3% | $21.38 | $21.76 | $21.24 | 338,697 |
- Ticker
- Munich:29A
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 11, 2026
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
Latest earnings call · Nov 5, 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 5, 2026
Q3 2026 Earnings Presentation
Earnings · 27 slides
Latest news
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
Nov 11, 2026
Closed $28.60 (-1.6%) on Nov 11, 2026
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Nov 5, 2026
Closed $28.49 (+3.0%) on Nov 6, 2026
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
Oct 29, 2026
Closed $26.93 (+2.3%) on Oct 29, 2026
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Sep 1, 2026
Closed $22.96 (+1.9%) on Sep 1, 2026
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Aug 6, 2026
Closed $20.78 (+4.9%) on Aug 7, 2026
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Jul 29, 2026
Closed $20.58 (+2.1%) on Jul 29, 2026
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
May 27, 2026
Closed $19.10 (+1.5%) on May 27, 2026
Q1 Financial Results (news)
May 8, 2026
Closed $19.00 (-20.9%) on May 8, 2026
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
May 7, 2026
Closed $24.03 (+0.5%) on May 7, 2026
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
May 6, 2026
Closed $23.90 (+2.2%) on May 6, 2026
Amphastar Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 20 in the last 12 months · 133 in all · newest Nov 11, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 5, 2026
- Decks
- 31 decks · latest Nov 5, 2026
Where Amphastar Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AMPH · Home listing | NASDAQ | United States | USD |
| LS Exchange:A11664 | LS Exchange | Germany | EUR |
| gettex:29A | gettex | Germany | EUR |
| Lang & Schwarz:A11664 | Lang & Schwarz | Germany | EUR |
| BOATS:AMPH | BOATS | United States | USD |
| Tradegate:29A | Tradegate | Germany | EUR |
| Frankfurt:29A | Frankfurt | Germany | EUR |
| Dusseldorf:29A | Dusseldorf | Germany | EUR |
| Munich:29A · This page | Munich | Germany | EUR |
| Stuttgart:29A | Stuttgart | Germany | EUR |
Valuation
P/E 12.2× against a median of 36.5×: the lowest of 5 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $976.8M USD
- P/E
- 12.2×
- EV/sales
- 1.3×
- EV/EBITDA
- 5.6×
- Price/book
- 1.5×
- Gross margin
- 46.8%
- Operating margin
- 18.7%
- Net margin
- 13.3%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.52
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. · NASDAQ:AMPH | US$1.20B | US$976.8M | 12.2× | 1.3× | 5.6× | 1.5× | 13.3% | 0.0× | 0.52 |
| Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A · SZSE:300026 | US$1.30B | US$1.07B | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A · SZSE:002099 | US$1.30B | US$1.17B | n/a | 3.9× | n/a | 1.9× | −11.6% | 0.0× | n/a |
| Concord Biotech Ltd. · NSE:CONCORDBIO | US$1.24B | US$1.19B | 40.6× | 9.4× | 27.3× | 5.5× | 24.1% | 0.0× | n/a |
| Zhejiang Xianju Pharmaceutical Co., Ltd. Class A · SZSE:002332 | US$1.23B | US$1.07B | 17.7× | 1.9× | n/a | 1.4× | 12.0% | 0.0× | n/a |
| Hualan Biological Vaccine Inc. Class A · SZSE:301207 | US$1.16B | US$844.0M | 167× | 8.1× | n/a | 1.5× | 6.6% | 0.0× | n/a |
| Idorsia Ltd. · SIX:IDIA | US$1.15B | US$2.66B | n/a | 10.2× | n/a | n/a | −128.8% | n/a | n/a |
| Chongqing Lummy Pharmaceutical Co., Ltd. Class A · SZSE:300006 | US$1.15B | US$1.03B | n/a | 9.6× | n/a | 4.5× | −16.6% | 0.1× | n/a |
| Harrow, Inc. · NASDAQ:HROW | US$1.14B | US$1.36B | n/a | 4.5× | 188× | 39.1× | −9.4% | 10.0× | 1.31 |
| Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550 | US$1.12B | US$927.8M | 32.3× | 4.1× | n/a | 2.7× | 15.3% | 0.0× | n/a |
| GC Biopharma Corp. · KRX:006280 | US$1.11B | US$1.31B | n/a | 0.9× | 13.2× | 1.2× | −2.5% | 0.3× | n/a |
| Median of the others | US$1.15B | US$1.12B | 36.5× | 4.5× | 27.3× | 1.9× | −2.5% | 0.0× | 1.31 |
Forecasts
6 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 24.50 USD · Analysts' mean
- EPS, year to Dec 2026
- 3.20 · 7 analysts
- Revenue, year to Dec 2026
- 758.5M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jack Zhang | Chief Executive Officer, President, Chief Scientific Officer, and Director |
| Mary Luo | Chief Operating Officer, Chief Scientist, and Chairwoman of the Board of Director |
Board
| Director | Role |
|---|---|
| Mary Luo | Chief Operating Officer, Chief Scientist, and Chairwoman of the Board of Director |
| Anthony T. Pierce | Director |
| Bill Peters | Director |
| David R. Gaugh | Director |
| Diane G. Gerst | Director |
| Gayle M. Deflin | Director |
| Howard Lee | Director |
| Jack Zhang | Chief Executive Officer, President, Chief Scientific Officer, and Director |
| Jacob Liawatidewi | Director |
| Michael A. Zasloff | Director |
| Richard Prins | Lead Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 2026 Earnings Call | Thu, May 07, 2026 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 5:00 AM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 2025 Earnings Call | Wed, May 07, 2025 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 5:00 PM ET | Replay |
| Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 2024 Earnings Call | Wed, May 08, 2024 · 5:00 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +3.0% |
| Q2 2026 | Aug 6, 2026 · After close | +4.9% |
| Q1 2026 | May 7, 2026 · After close | −20.9% |
| Q4 2025 | Feb 26, 2026 | −27.7% |
| Q3 2025 | Nov 6, 2025 · After close | −0.8% |
| Q2 2025 | Aug 7, 2025 · After close | +10.1% |
| Q1 2025 | May 7, 2025 · After close | +0.9% |
| Q4 2024 | Feb 26, 2025 · After close | +0.9% |
| Q3 2024 | Nov 6, 2024 · After close | −13.7% |
| Q2 2024 | Aug 7, 2024 · After close | +13.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +0.5% |
| Q4 2023 | Feb 28, 2024 · After close | −14.9% |
| Q3 2023 | Nov 8, 2023 · After close | +15.4% |
| Q2 2023 | Aug 8, 2023 · After close | −4.3% |
| Q1 2023 | May 9, 2023 · After close | +13.0% |
| Q4 2022 | Feb 28, 2023 · After close | +14.8% |
| Q3 2022 | Nov 7, 2022 · After close | −9.4% |
| Q2 2022 | Aug 8, 2022 · After close | −15.1% |
| Q1 2022 | May 9, 2022 · After close | +7.0% |
| Q4 2021 | Mar 10, 2022 · After close | +12.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 27 slides | Nov 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 27 slides | Aug 6, 2026 |
| 2026 Bank of America Health Care Conference | Conference | 27 slides | May 13, 2026 |
| 25th Annual Needham Virtual Healthcare Conference (April 2026) | Conference | 31 slides | Apr 14, 2026 |
| Barclays 28th Annual Global Healthcare Conference 2026 | Conference | 31 slides | Mar 11, 2026 |
| Piper Sandler 37th Annual Healthcare Conference 2025 | Conference | 30 slides | Dec 3, 2025 |
| Investor Presentation (August 2025) | Investor deck | 26 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 26 slides | May 2025 |
| 24th Annual Needham Virtual Healthcare Conference 2025 | Conference | 26 slides | Apr 9, 2025 |
| Investor Presentation (February 2025) | Investor deck | 26 slides | February 2025 |
All 31 decks
IPO
Priced at US$7.00 a share on Jun 24, 2014.
- Price
- US$7.00 a share
- Shares offered
- 8,000,000 shares of common stock · 4,640,000 from the company and 3,360,000 from selling shareholders
- Offering size
- US$56 million
- Underwriters' option
- Up to 1,200,000 more shares
- Listing
- AMPH on the Nasdaq Global Select Market
- Underwriters
- Jefferies, BMO Capital Markets, Piper Jaffray, Needham & Company · In the order on the cover
- Shares delivered
- On or about Jun 30, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 16, 2013 |
| Filed publicly | May 20, 2014 |
| Amended 3 times | Newest Jun 18, 2014 |
| Shares registered with an exchange | Jun 18, 2014 |
| Declared effective by the SEC | Jun 24, 2014 |
| Final prospectus, with the price | Jun 25, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 25, 2014 |
| FWP · Free writing prospectus | Jun 25, 2014 |
| S-1MEF · Registration of more shares for the same offering | Jun 25, 2014 |
| EFFECT · Notice that a registration is effective | Jun 24, 2014 |
| CORRESP · Letter to the SEC | Jun 19, 2014 |
| CORRESP · Letter to the SEC | Jun 19, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Jun 19, 2014 |
| S-1/A · Registration statement, amended | Jun 18, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 18, 2014 |
| S-1/A · Registration statement, amended | Jun 13, 2014 |
All 24 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 12, 2014 |
| CORRESP · Letter to the SEC | Jun 9, 2014 |
| CORRESP · Letter to the SEC | Jun 5, 2014 |
| S-1/A · Registration statement, amended | Jun 5, 2014 |
| UPLOAD · Letter from the SEC | May 30, 2014 |
| S-1 · Registration statement | May 20, 2014 |
| CORRESP · Letter to the SEC | May 19, 2014 |
| DRS/A · Draft registration statement, amended | May 14, 2014 |
| UPLOAD · Letter from the SEC | Apr 14, 2014 |
| DRS/A · Draft registration statement, amended | Apr 3, 2014 |
| UPLOAD · Letter from the SEC | Feb 19, 2014 |
| DRS/A · Draft registration statement, amended | Feb 7, 2014 |
| UPLOAD · Letter from the SEC | Jan 10, 2014 |
| DRS · Draft registration statement | Dec 16, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 25, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 719.9M | 732.0M | 644.4M | 499.0M | 437.8M | 349.8M | 322.4M | 294.7M | 240.2M | 255.2M |
| Cost of revenue | 363.8M | 358.1M | 293.3M | 250.1M | 238.0M | 206.5M | 190.4M | 187.7M | 149.7M | 151.0M |
| Gross profit | 356.1M | 373.9M | 351.1M | 248.9M | 199.7M | 143.3M | 131.9M | 107.0M | 90.5M | 104.2M |
| Research and development | 85.8M | 73.9M | 73.7M | 74.8M | 60.9M | 67.2M | 68.9M | 57.6M | 43.5M | 41.5M |
| Selling, general and administrative | 85.9M | 56.7M | 51.5M | 45.1M | 51.4M | 50.4M | 50.3M | 49.9M | 44.5M | 41.8M |
| Operating income | 140.4M | 205.4M | 197.0M | 107.5M | 69.9M | 11.0M | -39.0K | -8.62M | -1.27M | 15.4M |
| Depreciation and amortization | 31.6M | 28.2M | 25.7M | 12.6M | 10.2M | 9.03M | 7.06M | 6.05M | 6.42M | 12.2M |
| EBITDA | 172.1M | 233.7M | 222.7M | 120.1M | 80.1M | 20.0M | 7.02M | -2.57M | 5.15M | 27.5M |
| Interest expense | 25.5M | 30.3M | 27.2M | 1.85M | 885.0K | 374.0K | 119.0K | 243.0K | 826.0K | 1.02M |
| Income before tax | 123.6M | 189.8M | 171.4M | 116.0M | 84.1M | 4.64M | 60.2M | -9.93M | 1.25M | 14.6M |
| Income tax | 25.5M | 29.7M | 31.8M | 23.5M | 20.6M | 3.54M | 13.7M | -3.27M | -2.40M | 4.81M |
| Net income | 98.1M | 159.5M | 137.5M | 91.4M | 62.1M | 1.40M | 48.9M | -5.74M | 3.65M | 9.82M |
| Earnings per share, basic | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 | 0.03 | 1.04 | -0.12 | 0.08 | 0.22 |
| Earnings per share, diluted | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 | -0.12 | 0.08 | 0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 170.2M | 151.6M | 144.3M | 156.1M | 126.4M | 92.6M | 73.7M | 86.3M | 65.6M | 72.4M |
| Short-term investments | 112.6M | 70.0M | 112.5M | 19.7M | 10.3M | 13.0M | 11.7M | 2.83M | 2.63M | 527.0K |
| Receivables | 143.6M | 136.3M | 114.9M | 88.8M | 78.8M | 66.0M | 45.4M | 52.2M | 36.0M | 26.8M |
| Inventory | 176.9M | 153.7M | 105.8M | 103.6M | 92.8M | 96.8M | 110.5M | 69.3M | 63.6M | 79.8M |
| Current assets | 636.0M | 534.1M | 489.6M | 378.3M | 318.1M | 279.7M | 255.2M | 220.3M | 187.8M | 184.1M |
| Property, plant and equipment | 310.6M | 297.3M | 282.7M | 238.3M | 244.2M | 260.1M | 233.9M | 210.4M | 180.5M | 152.9M |
| Goodwill | 3.40M | 3.05M | 3.22M | 3.13M | 3.31M | 3.94M | 3.63M | 3.95M | 4.46M | 3.98M |
| Total assets | 1.63B | 1.58B | 1.51B | 742.0M | 671.5M | 631.2M | 587.0M | 513.6M | 451.1M | 427.7M |
| Accounts payable | 32.6M | 30.5M | 25.4M | 20.5M | 22.2M | 24.4M | 25.1M | 31.3M | 16.6M | 19.9M |
| Current liabilities | 158.2M | 173.8M | 225.4M | 94.9M | 103.8M | 112.2M | 90.0M | 106.8M | 67.2M | 60.6M |
| Long-term debt | 619.7M | 613.5M | 603.2M | 76.6M | 78.2M | 45.9M | 46.3M | 49.1M | 45.7M | 36.0M |
| Total debt | 621.3M | 613.8M | 603.6M | 79.7M | 80.4M | 58.2M | 54.1M | 50.2M | 47.2M | 37.7M |
| Total liabilities | 840.5M | 845.2M | 873.5M | 213.3M | 226.0M | 182.5M | 159.4M | 149.2M | 117.3M | 98.5M |
| Shareholders' equity | 788.8M | 732.3M | 639.4M | 528.7M | 445.5M | 402.3M | 381.4M | 332.4M | 333.7M | 329.3M |
| Shares outstanding | 45.6M | 47.6M | 48.1M | 48.1M | 47.7M | 47.5M | 46.6M | 46.6M | 46.6M | 46.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 156.1M | 213.4M | 183.5M | 89.2M | 98.0M | 57.3M | 41.8M | 38.2M | 39.2M | 38.6M |
| Capital spending | -34.9M | -41.0M | -38.2M | -24.0M | -27.5M | -33.9M | -41.6M | -46.8M | -35.1M | -21.4M |
| Free cash flow | 121.2M | 172.3M | 145.3M | 65.1M | 70.5M | 23.4M | 207.0K | -8.62M | 4.11M | 17.2M |
| Cash from investing | -70.3M | -124.9M | -649.1M | -32.8M | -28.7M | -36.4M | -50.5M | -42.2M | -36.9M | -39.5M |
| Cash from financing | -67.4M | -81.0M | 454.1M | -26.4M | -37.0M | -2.25M | -3.78M | 25.0M | -7.72M | 7.14M |
| Dividends paid | -454.1M | -15.7M | -15.9M | -23.2M | -20.3M | 0 | -10.2M | |||
| Share buybacks | -75.6M | -85.5M | -58.1M | -39.9M | -28.9M | -24.4M | -22.3M | -25.0M | -30.7M | -9.91M |
| Change in cash | 18.6M | 7.31M | -11.8M | 29.7M | 32.1M | 19.0M | -12.7M | 20.7M | -4.89M | 6.28M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 13, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 6, 2026 | Material contract | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 18, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 2, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 6, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 30, 2024 | Material contract | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 31, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 19, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 12, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 12, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 6, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
This page holds 200 of 960 filings. Open Filings
Cap table
Built by 6ix from Amphastar Pharmaceuticals, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 42,652,154
- Fully diluted
- 42,652,154
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,652,154 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 42,652,154 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Prins Other companies: IGC Pharma, Inc. (Chairman · Since at least Mar 31, 2025) | Lead Independent Director · Since at least Aug 19, 2024 |
| Anthony T. Pierce | Director · Since at least Jul 9, 2026 |
| Bill Peters | Director · Since at least May 6, 2026 |
| David R. Gaugh | Director · Since at least Jul 18, 2025 |
| Diane G. Gerst | Director · Since at least Jun 1, 2026 |
| Floyd F Petersen | Director · Since at least Oct 4, 2017 |
| Gayle M. Deflin | Director · Since at least Jun 1, 2026 |
| Howard Lee | Director · Since at least Jun 3, 2026 |
| Jack Zhang | Chief Executive Officer, President, Chief Scientific Officer, and Director · Since at least Aug 6, 2026 |
| Jacob Liawatidewi | Director · Since at least May 27, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Mary Luo | COO, Chief Scientist, Chairman, Director · Since at least Nov 13, 2017 |
| Michael A. Zasloff | Director · Since at least May 16, 2022 |
| Rong Zhou | SENIOR EVP, PRODUCTION CENTER · Since at least Dec 1, 2023 |
Log in to ask 6ix AI your own questions about Amphastar Pharmaceuticals, Inc.